All News

Vincent Chung, MD, discusses key findings from the NAPOLI-3 trial and offers guidance for pharmacists on managing toxicities, adjusting dosing, and supporting patients receiving NALIRIFOX for metastatic pancreatic ductal adenocarcinoma.

About 10% of patients report a penicillin allergy, but only around 1% are truly allergic. Recommending penicillin allergy testing can help patients determine whether they have a true allergy.

CDC urges all US travelers to get vaccinated for measles, mumps, and rubella (MMR) amid rising measles cases, emphasizing prevention as key to combating outbreaks.

Although women might benefit from fattier breakfasts, men could respond best to carbohydrates.

Subcutaneous immunoglobulin (SCIg) is a hopeful alternative to intravenous immunoglobulin in patients with inflammatory myositis due to a lack of adverse effects and fewer financial constraints.

Saad Usmani, MD, MBA, FACP, FASCO, explores treatment duration, patient characteristics, and toxicity profiles in transplant-ineligible patients with newly diagnosed multiple myeloma.

New findings show LYR-210's potential to significantly alleviate chronic rhinosinusitis symptoms, offering hope for patients with nasal inflammation and polyps.

Results from the NeoADAURA trial demonstrate the sustained efficacy of osimertinib in patients with epidermal growth factor receptor-mutated (EGFRm) non-small-cell lung cancer (NSCLC).

New treatments for metabolic dysfunction-associated steatohepatitis (MASH)–related cirrhosis address unique challenges in drug development.

Ibrutinib plus venetoclax shows promising long-term survival rates, including those who are considered high risk.

Infectious Disease Society of America guidance defines difficult-to-treat resistant Pseudomonas aeruginosa as resistance to all first-line agents.

New research finds that adding carboplatin to paclitaxel and adjuvant chemotherapy shows no significant survival benefits in triple-negative breast cancer (TNBC).

Establishing a strong foundation and effective networking strategies and pursuing opportunities are key.

Explore the latest advancements in myelofibrosis treatment, focusing on JAK inhibitors and pegylated interferons for improved patient outcomes.

Amanda Gronniger, PharmD, CPh, BCCP, discusses practical strategies pharmacists can use to improve cholesterol management, from lifestyle counseling to emerging therapies.

The FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer after positive results in the ARANOTE clinical trial.

The 2025 ASCO Annual Meeting discusses the latest advancements in understanding and treating precursor diseases.

Chip Hailey, a 74-year-old pharmacist with hemophilia B, shares how gene therapy has liberated him from decades of challenging treatment and restored his independence.

Clairity Breast's FDA-approved AI platform revolutionizes breast cancer risk prediction, enhancing early detection and personalized prevention strategies.

Electronic prior authorization (EPA) technology can streamline the complex process of obtaining prior authorizations for GLP-1 medications.

Zongertinib shows promising efficacy and safety for HER2-mutant NSCLC, with a 71% response rate and low toxicity, paving the way for future treatments.

Ralph Riello, PharmD, BCPS, a board-certified clinical pharmacy specialist at the Yale University School of Medicine, discusses challenges in implementation for novel cardiovascular treatments and interventions.

The CDC has updated its COVID-19 vaccine guidance for children and pregnant individuals, sparking a debate among health experts and concerns over insurance coverage.

The NJSHP's 2nd Annual Symposium fosters networking and education for pharmacy professionals, featuring expert insights on compliance and regulation in pharmacy compounding.

A clinical trial shows tebipenem pivoxil hydrobromide (Tebipenem HBr; Spero Therapeutics and GSK) effectively treats complicated urinary tract infections (cUTIs), potentially transforming patient care and reducing hospital costs.

Amid intensified scrutiny of COVID-19 vaccines at HHS, Moderna’s mRNA-1283 COVID-19 vaccine was granted FDA approval for patients 65 years and older and patients aged 12 to 64 years with at least 1 or more underlying risk factors for severe COVID-19.

Laura Momoko Asakura, PharmD, BCOP, BCSPS, discusses the equitable use of oncology treatment pathway tools, highlighting that their utilization remains consistent across patient groups regardless of race, ethnicity, or insurance status.

A study reveals a 14-gene assay guides chemotherapy decisions effectively in patients with early-stage non-small cell lung cancer (NSCLC).

Saad Usmani, MD, MBA, FACP, FASCO, discusses the subgroup analysis of transplant-ineligible patients with newly diagnosed multiple myeloma from the CEPHEUS trial.

The FDA designated Hadlima as an interchangeable biosimilar to Humira, enhancing patient access and potential savings for various conditions.